Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292247 | 0.91 | — | — | |
| SCHEMBL9214163 | 0.88 | USP2 (0.40) | USP2ALDH1A1ALOX15TDP1 | |
| SCHEMBL7186562 | 0.86 | USP2 (0.37) | USP2ALDH1A1ALOX15TDP1 | |
| SCHEMBL6315739 | 0.86 | USP2 (0.42) | USP2ALDH1A1ALOX15TDP1 | |
| SCHEMBL6014417 | 0.82 | — | — | |
| SCHEMBL11788866 | 0.79 | ALDH1A1 (0.57) | USP2ALDH1A1ALOX15TDP1 | |
| SCHEMBL9209673 | 0.79 | ALDH1A1 (0.57) | USP2ALDH1A1ALOX15TDP1 | |
| SCHEMBL16398713 | 0.79 | USP2 (0.53) | USP2ALDH1A1ALOX15TDP1CHRNB2 | |
| SCHEMBL11785211 | 0.79 | ALDH1A1 (0.57) | USP2ALDH1A1ALOX15TDP1 | |
| SCHEMBL16402730 | 0.79 | ALDH1A1 (0.57) | USP2ALDH1A1ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0061872-B1 | ETHYLENEGLYCOL DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1985-08-07 | — | — | EP | claimed |
| EP-0040039-B1 | ETHYLENE GLYCOL DERIVATIVES OF AMMONIOETHYL PHOSPHATE, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-08-01 | — | — | EP | claimed |
| EP-0035375-B1 | CARBAMIC ACID ESTERS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1983-08-10 | — | — | EP | claimed |
| US-20050152959-A1 | Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell | TRANSGENE S. A. (FR) | 2005-07-14 | — | — | US | disclosed |
| US-20050112187-A1 | Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal | TRANSGENE S.A. (FR) | 2005-05-26 | — | — | US | disclosed |
| EP-1465597-A2 | USE OF A LYSOLIPID FOR THE PREPARATION OF A COMPOSITION FOR TRANSFECTION OF A POLYNUCLEOTIDE INTO A CELL | TRANSGENE S.A. (FR) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003052095-A2 | USE OF A LYSOLIPID FOR THE PREPARATION OF A COMPOSITION FOR TRANSFECTION OF A POLYNUCLEOTIDE INTO A CELL | TRANSGENE S.A. (FR) | 2003-06-26 | — | — | WO | disclosed |
| EP-1289568-A2 | COMBINATION PRODUCT FOR CARRYING OUT A CYTOTOXIC TREATMENT IN A MAMMAL | TRANSGENE S.A. (FR) | 2003-03-12 | — | — | EP | disclosed |
| US-20020025941-A1 | Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal | TRANSGENE S.A. (FR) | 2002-02-28 | — | — | US | disclosed |
| WO-2001095946-A2 | COMBINATION PRODUCT FOR CARRYING OUT A CYTOTOXIC TREATMENT IN A MAMMAL | TRANSGENE S.A. (FR) | 2001-12-20 | — | — | WO | disclosed |
| US-4935520-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| US-4542219-A | ANTITUMOR, AGRICULTURAL FUNGICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-09-17 | — | — | US | disclosed |
| EP-0061872-B1 | ETHYLENEGLYCOL DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1985-08-07 | — | — | EP | disclosed |
| EP-0040039-B1 | ETHYLENE GLYCOL DERIVATIVES OF AMMONIOETHYL PHOSPHATE, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-08-01 | — | — | EP | disclosed |
| EP-0108565-A2 | Phospholipids, their production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1984-05-16 | — | — | EP | disclosed |
| US-4408052-A | FUNGICIDES AND ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-10-04 | — | — | US | disclosed |
| EP-0035375-B1 | CARBAMIC ACID ESTERS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1983-08-10 | — | — | EP | disclosed |
| EP-0061872-A1 | Ethyleneglycol derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-10-06 | — | — | EP | disclosed |
| EP-0040039-A1 | Ethylene glycol derivatives of ammonioethyl phosphate, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-11-18 | — | — | EP | disclosed |
| EP-0035375-A1 | Carbamic acid esters, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050152959-A1 | Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell | LPCAT1, LPCAT3, LCLAT1 | USP2 3562/4885ALDH1A1 4736/4885ALOX15 771/4885 |
| US-20050112187-A1 | Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal | TYMP, PHOSPHO1, PIGS | USP2 3608/4885ALDH1A1 4291/4885ALOX15 1846/4885 |
| US-20020025941-A1 | Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal | TYMP, PHOSPHO1, PIGS | USP2 3608/4885ALDH1A1 4291/4885ALOX15 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.